Pharma channel feed

J&J poach­es Bay­er ex­ec Jim Swan­son as chief in­for­ma­tion of­fi­cer

6 years ago
People

King Keytru­da: Mer­ck­'s PD-1 star scores #1 po­si­tion and $22B+ pre­dic­tion in an­oth­er top 10 block­buster list for 2025

6 years ago

Phar­ma to blame for im­peach­ment woes? Yep, Pres­i­dent Trump just sug­gest­ed that about Amer­i­ca's least fa­vorite in­dus­try

6 years ago

Gilead scores PrEP ap­proval for De­scovy — kick­ing off mar­ket­ing push be­fore Tru­va­da gener­ics swarm

6 years ago
FDA+

In an un­usu­al move, ICER re­scinds draft re­port on JAK drugs for rheuma­toid arthri­tis to re­vise its mod­el­ing ap­proach

6 years ago
FDA+

J&J set­tles Ohio opi­oid case for $20.4M, avoids loom­ing tri­al

6 years ago

No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

6 years ago
R&D

J&J's em­bat­tled In­vokana gets a boost as FDA ex­pands la­bel

6 years ago
FDA+

Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

6 years ago
R&D

Agios lines up sol­id PhI­II da­ta to back Tib­sovo's use in bile duct can­cer — ahead of planned sN­DA

6 years ago
R&D

FDA clears short­er treat­ment reg­i­men for Ab­b­Vie's hep C treat­ment, Mavyret. Will pa­tients ben­e­fit?

6 years ago
R&D
FDA+

Mer­ck­'s top can­cer team basks in the warm light of pos­i­tive Keytru­da da­ta from a land­mark study for hard-to-treat breast can­cer

6 years ago
R&D

No­var­tis, Eli Lil­ly mar­quee pos­i­tive sur­vival da­ta for CDK 4/6 fran­chis­es — but can they ac­tu­al­ly beat Pfiz­er's block­buster?

6 years ago
R&D

Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

6 years ago
R&D

As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

6 years ago
R&D

PRI­MA vs PAO­LA: GSK and Mer­ck/As­traZeneca square off in a high-pro­file PARP show­down at ES­MO

6 years ago
R&D

Bris­tol-My­ers Squib­b's Op­di­vo could­n't top­ple Nex­avar in HCC — but will bet­ter safe­ty pro­file win over physi­cians?

6 years ago
R&D

Pfiz­er's JAK in­hibitor clears sec­ond piv­otal eczema study, but can it top­ple Re­gen­eron's Dupix­ent?

6 years ago
R&D

Darza­lex from J&J, Gen­mab scores FDA ap­proval in front­line mul­ti­ple myelo­ma use as Sanofi ri­val looms

6 years ago
R&D

Deep im­pact: Drugs to watch in Q3 — PBM analy­sis

6 years ago
R&D

GSK in­fus­es $120M in­to next-gen man­u­fac­tur­ing fa­cil­i­ties at Up­per Meri­on, PA

6 years ago

Re­pub­li­cans re­buke Pelosi drug pric­ing bill

6 years ago
FDA+

Top GSK/Vi­iV sci­en­tist who co-in­vent­ed an HIV block­buster books a trip to biotech

6 years ago
People
R&D

'Worse than ever,' Boston's biotechs stare down traf­fic cri­sis — prompt­ing call for more re­mote work­ing, flex hours

6 years ago
First page Previous page 261262263264265266267 Next page Last page
A service from the Financial Times